• IDRA-21 - Zion Pharma

IDRA-21 powder

8,50135,00

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

SKU: idra-21-powder

ACTIVE INGREDIENT: IDRA-21 >99%

OTHER NAMES: 2H-1,2,4-Benzothiadiazine, 7-chloro-3,4-dihydro-3-methyl-, 1,1-dioxide

CAS NUMBER: 22503-72-6

ATC CODE: none

FORMULA: C8H9ClN2O2S

ITEM TYPE: Powder

QUANTITY PER PACK: 1 g to 20 g

SERVINGS PER PACK: not specified

SUGGESTED USE: not specified

STORAGE: Store in a cool and dry place. Keep away from direct sunlight and heat.

WARNING: Keep out of reach of children. Do not take this or any other supplement if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions, and/or taking prescription drugs or over the counter medications.

DISCLAIMER: Always consult with a qualified health physician before taking any new dietary supplement. This product is not intended to diagnose, treat, cure, or prevent any diseases.

SCOOPS: This product includes a measuring scoop  3 mg/13 mg.

The product is not intended for human use. For laboratory use only.

IDRA-21 improving learning and memory

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10–30 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 may not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

In comparison to the ampakines or benzoylpiperidine-derived AMPA receptor potentiators, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

Wikipedia